Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03129347 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03129347 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 14 participants.
The verdict
NCT03129347, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will be to compare the pharmacokinetics of nalmefene administration intranasal with and without an absorption enhancer compared to an intramuscular injection.
Interventions
- DRUG Nalmefene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2017-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03129347
The ClinicalTrials.gov registry entry for NCT03129347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nalmefene is the first listed.
NCT03129347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03129347 about?
NCT03129347 is a clinical study titled "Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers". This study will be to compare the pharmacokinetics of nalmefene administration intranasal with and without an absorption enhancer compared to an intramuscular injection.
What is the current status of trial NCT03129347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-06-01. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT03129347?
The interventions under investigation include: Nalmefene (DRUG).
Who is sponsoring clinical trial NCT03129347?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.